Trimethobenzamide

DB00662ApprovedInvestigationalSmall moleculeAntiemetics

Trimethobenzamide is an antiemetic used to treat postoperative nausea and vomiting and nausea associated with gastroenteritis. Its actions are unclear but most likely involves the chemoreceptor trigger zone (CTZ).

Mechanism: The mechanism of action of trimethobenzamide as determined in animals is obscure, but may involve the chemoreceptor trigger zone (CTZ), an area in the medulla oblongata through which emetic impulses are conveyed to the vomiting center; direct impulses to the vomiting center apparently are not similarly inhibited.
Curator reviewed
Primary indication: For the treatment of postoperative nausea and vomiting and for nausea associated with gastroenteritis.Curator reviewed · 3 structured indications
Formula / weight: C₂₁H₂₈N₂O₅ · 388.4574 g/mol (avg)
First approval: United States, 1974
Brand names: Tigan

Resolves to

Compound

UNIIW2X096QY97CAS138-56-7ChEMBLCHEMBL1201256ChEBI27796PubChem5577KEGGD08643

Clinical / RWD

RxNorm38685ATCR06AA10PharmGKBPA164764516

Structure

InChIKeyFEZBIKUBAYAZIU-UHFFFAOYSA-NSMILESCOC1=CC(=CC(OC)=C1OC)C(=O)NCC1=CC=C(OCCN(C)C)C=C1

Targets

P14416DRD2

What you can answer from here — as of September 11, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

677Drug interactionsStructured to mechanism, not free text

5Clinical trialsPhase, status and sponsor resolved per trial

3Structured indicationsCondition, population, route and combination as fields, not prose

68Marketed productsAcross 2 countries and 32 labellers

1ATC codeIncluding every combination product, plus 14 drug categories

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with Trimethobenzamide, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Log In Paid Account Log In